Neutralization of primary HIV-1SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1SF2 gp120

被引：5

作者：

Davis, D

Donners, H

Willems, B

Lövgren-Bengtsson, K

Åkerblom, L

Vanham, G

Barnett, S

Morein, B

Heeney, JL

van der Groen, G

机构：

[1] Inst Trop Med, Dept Microbiol, Virol Lab, B-2000 Antwerp, Belgium

[2] Natl Vet Inst, Biomed Ctr, Dept Virol, S-75007 Uppsala, Sweden

[3] Chiron Corp, Emeryville, CA 94608 USA

来源：

VACCINE | 2004年 / 22卷 / 5-6期

关键词：

envelope glycoprotein; DNA vaccine; primary HIV-1 isolates; recombinant prime; peptide boost; neutralizing antibodies;

D O I：

10.1016/j.vaccine.2003.08.031

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Phase III efficacy trials of recombinant human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins were postponed. In Phase I and II trials these candidate vaccines had failed to induce neutralizing antibodies against virus which had been isolated by co-culture with human peripheral blood mononuclear cells (PBMC). The aim of the present study was to determine assay conditions for detecting neutralization of primary HIV-1 isolates with sera from immunized individuals. We show that in two immunogenicity trials in rhesus macaques, recombinant HIV-1 SF2 gp120 induced antibodies which neutralized the primary HIV-1 SF13 isolate. Statistically significant in vitro neutralization required assays in which the incubation phase was extended. Sterile immunity was only seen with the highest level of neutralization, induced by a recombinant prime, peptide boost strategy. We recommend that neutralization assays with extended incubation phases should be used to monitor Phase III efficacy trials. (C) 2003 Elsevier Ltd. All rights reserved.

引用

收藏

页码：747 / 754

页数：8

相关论文

共 29 条

[1] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].

Baba, TW ;

Liska, V ;

Hofmann-Lehmann, R ;

Vlasak, J ;

Xu, WD ;

Ayehunie, S ;

Cavacini, LA ;

Posner, MR ;

Katinger, H ;

Stiegler, G ;

Bernacky, BJ ;

Rizvi, TA ;

Schmidt, R ;

Hill, LR ;

Keeling, ME ;

Lu, YC ;

Wright, JE ;

Chou, TC ;

Ruprecht, RM .

NATURE MEDICINE, 2000, 6 (02) :200-206

[2] Design and evaluation of an in-house HIV-1 (group M and O), SIVmnd and SIVcpz antigen capture assay [J].

Beirnaert, E ;

Willems, B ;

Peeters, M ;

Bouckaert, A ;

Heyndrickx, L ;

Zhong, P ;

Vereecken, K ;

Coppens, S ;

Davis, D ;

Ndumbe, P ;

Janssens, W ;

van der Groen, G .

JOURNAL OF VIROLOGICAL METHODS, 1998, 73 (01) :65-70

[3] Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand [J].

Berman, PW ;

Huang, W ;

Riddle, L ;

Gray, AM ;

Wrin, T ;

Vennari, J ;

Johnson, A ;

Klaussen, M ;

Prashad, H ;

Köhne, C ;

DeWit, C ;

Gregory, TJ .

VIROLOGY, 1999, 265 (01) :1-9

[4] Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 [J].

Bures, R ;

Gaitan, A ;

Zhu, TF ;

Graziosi, C ;

McGrath, KM ;

Tartaglia, J ;

Caudrelier, P ;

EL Habib, R ;

Klein, M ;

Lazzarin, A ;

Stablein, DM ;

Deers, M ;

Corey, L ;

Greenberg, ML ;

Schwartz, DH ;

Montefiori, DC .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) :2019-2035

[5]

CHENGMAYER C, 1988, ANN NEUROL S, V23, P58

[6]

Cohen J, 2001, SHOTS DARK WAYWARD S

[7] ANTISERA RAISED AGAINST THE 2ND VARIABLE REGION OF THE EXTERNAL ENVELOPE GLYCOPROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CROSS-NEUTRALIZE AND SHOW AN INCREASED NEUTRALIZATION INDEX WHEN THEY ACT TOGETHER WITH ANTISERA TO THE V3 NEUTRALIZATION EPITOPE [J].

DAVIS, D ;

STEPHENS, DM ;

CARNE, CA ;

LACHMANN, PJ .

JOURNAL OF GENERAL VIROLOGY, 1993, 74 :2609-2617

[8] HIV-1 candidate vaccines can induce antibodies which share specificity with human monoclonal antibodies capable of neutralizing primary isolates [J].

Davis, D .

VACCINE, 1996, 14 (04) :353-354

[9] Epitopes corresponding to the envelope genetic subtype are present on the surface of free Virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases [J].

Davis, D ;

Donners, H ;

Willems, B ;

Vermoesen, T ;

Heyndrickx, L ;

Colebunders, R ;

van der Groen, G .

JOURNAL OF MEDICAL VIROLOGY, 2003, 71 (03) :332-342

[10] The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases [J].

Donners, H ;

Vermoesen, T ;

Willems, B ;

Davis, D ;

van der Groen, G .

VACCINE, 2003, 22 (01) :104-111